Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Nasal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Hong Kong | Philippines | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Influenza, Human|Asthma|Respiratory Tract Infections|Herpesviridae Infections|Communicable Diseases|Pneumonia
Phase 3: Chickenpox|Influenza, Human|Rubella|Healthy Volunteers
Phase 2: Influenza, Human|HIV Infections|Environmental Hypersensitivity|Egg Hypersensitivity|Acquired Immunodeficiency Syndrome
Phase 1: Influenza, Human|Zika Virus Infection|Pneumonia|Dengue|Kidney Cancer|Nose Cancer|Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06841913 |
SmokeyFlu | P4 |
Suspended |
Influenza, Human |
2028-12-31 |
2025-06-21 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
|
NCT07177417 |
EVax-3 | P4 |
Recruiting |
Influenza, Human |
2026-09-01 |
2025-09-18 |
Primary Endpoints |
|
NCT05921448 |
VAXXAIR | P1 |
Not yet recruiting |
Influenza, Human |
2026-04-30 |
2024-02-23 |
||
NCT04901455 |
1R01HL150081-01A1 | P1 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2026-03-01 |
2025-05-31 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
NCT04164212 |
IRB-300004274 | P4 |
Recruiting |
Influenza, Human |
2026-01-31 |
2025-12-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT01866540 |
LAIV-tonsilsv2 Version 2 | N/A |
Active, not recruiting |
Tonsillitis|Influenza, Human |
2025-12-31 |
2023-12-07 |
||
2023-506166-31-01 |
VAXXAIR TRIAL | P4 |
Not yet recruiting |
Influenza, Human |
2025-12-31 |
2025-05-02 |
Treatments |
|
NCT06501963 |
PRISM | P4 |
Completed |
Influenza, Human |
2025-04-01 |
2025-11-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03898986 |
FLU-TW | P1 |
Completed |
Influenza, Human |
2023-12-31 |
2024-02-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03884296 |
FLU-Tonsil | P4 |
Withdrawn |
Influenza, Human |
2023-11-17 |
2023-11-22 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01967238 |
TWA-0804 | P1 |
Terminated |
Pneumonia|Dengue|Zika Virus Infection|Influenza, Human |
2023-03-01 |
2024-09-20 |
Primary Endpoints |
|
NCT05290792 |
WE SENSE | N/A |
Completed |
Respiratory Tract Infections|Communicable Diseases|Influenza, Human |
2022-10-31 |
2023-11-02 |
Primary Endpoints|Treatments|Trial Status |
|
NCT03982069 |
STUDY19040242 | P4 |
Completed |
Influenza, Human |
2020-12-09 |
2021-10-15 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT02950688 |
URMC 15-001 | P1 |
Withdrawn |
Influenza, Human |
2020-12-01 |
2019-03-21 |
Treatments |
|
2018-003701-26 |
2018-003701-26 | P4 |
Completed |
Influenza, Human |
2019-12-04 |
2025-07-06 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
2017-000849-50 |
2017-000849-50 | P2 |
Completed |
Influenza, Human |
2019-09-27 |
2025-07-06 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03453801 |
SLVP030 | P1 |
Completed |
Influenza, Human |
2019-01-14 |
2020-02-15 |
||
NCT03088904 |
SLVP028 | P1 |
Completed |
Influenza, Human |
2018-12-12 |
2020-02-15 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT03028974 |
SLVP029 | P4 |
Completed |
Influenza, Human |
2017-11-20 |
2019-03-21 |
Treatments |
|
NCT03143101 |
FluMist | P4 |
Completed |
Influenza, Human |
2017-09-29 |
2019-03-21 |
Treatments |
|
NCT03502291 |
LAIV/EHPC | P4 |
Completed |
Influenza, Human|Pneumonia |
2017-05-01 |
2020-01-28 |
Primary Endpoints|Treatments |
|
2014-004634-26 |
LAIV and EHPC | P4 |
Completed |
Influenza, Human |
2017-04-30 |
2025-07-02 |
Treatments |
|
NCT02866942 |
SNIFFLE-4 | P4 |
Completed |
Asthma |
2017-03-01 |
2019-03-20 |
Treatments |
|
NCT02019745 |
P50HL120100-01 | N/A |
Completed |
Communicable Diseases|Respiratory Tract Infections|Influenza, Human|Tobacco Use Disorder |
2016-06-01 |
2019-03-20 |
Treatments |
|
NCT02549365 |
SNIFFLE-3 | P4 |
Completed |
Influenza, Human |
2016-04-01 |
2019-12-01 |
Patient Enrollment|Primary Endpoints|Treatments |